What is HC Wainwright’s Estimate for RNTX FY2030 Earnings?

Rein Therapeutics Inc. (NASDAQ:RNTX) – Equities researchers at HC Wainwright increased their FY2030 earnings per share estimates for shares of Rein Therapeutics in a report released on Tuesday, August 18th. HC Wainwright analyst B. Folkes now forecasts that the company will earn $0.56 per share for the year, up from their prior estimate of $0.55. HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Rein Therapeutics’ current full-year earnings is ($0.53) per share.

Rein Therapeutics (NASDAQ:RNTX) last announced its quarterly earnings data on Friday, August 14th. The company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.17.

Several other equities research analysts have also recently issued reports on RNTX. Weiss Ratings upgraded shares of Rein Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, August 3rd. Wall Street Zen raised shares of Rein Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, June 6th. Finally, Maxim Group initiated coverage on shares of Rein Therapeutics in a research note on Monday, July 20th. They set a “buy” rating and a $4.00 target price for the company. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $6.00.

Rein Therapeutics Trading Down 8.5%

Shares of RNTX opened at $0.77 on Wednesday. The business’s 50 day moving average is $0.88 and its 200 day moving average is $1.13. Rein Therapeutics has a 12-month low of $0.69 and a 12-month high of $2.18. The company has a market capitalization of $65.87 million, a PE ratio of -0.45 and a beta of 1.39.

Hedge Funds Weigh In On Rein Therapeutics

Several institutional investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC bought a new stake in Rein Therapeutics in the 2nd quarter worth approximately $344,000. Northwestern Mutual Wealth Management Co. bought a new position in shares of Rein Therapeutics during the 2nd quarter valued at approximately $68,000. Cable Car Capital LP bought a new position in shares of Rein Therapeutics during the 2nd quarter valued at approximately $588,000. Vanguard Group Inc. grew its holdings in shares of Rein Therapeutics by 32.2% in the third quarter. Vanguard Group Inc. now owns 1,168,407 shares of the company’s stock valued at $1,338,000 after purchasing an additional 284,300 shares in the last quarter. Finally, Susquehanna International Group LLP purchased a new position in shares of Rein Therapeutics in the third quarter valued at $35,000. Hedge funds and other institutional investors own 90.89% of the company’s stock.

Rein Therapeutics Company Profile

Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company’s core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.

The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.